Neuromodulation Therapy Articles & Analysis
35 news found
The clinical-stage company is developing a neuroprosthesis for the treatment of paralysis and the first endovascular implantable neuromodulation therapy. Future applications include the potential to diagnose and treat conditions of the nervous system, including Parkinson’s disease, epilepsy, depression, and hypertension. ...
The clinical-stage company is developing a neuroprosthesis for the treatment of paralysis and the first endovascular implantable neuromodulation therapy. Future applications include the potential to diagnose and treat conditions of the nervous system, including Parkinson’s disease, epilepsy, depression, and hypertension. ...
The Relivion DP is the first non-invasive, multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders. ...
Neurolief, a neurotechnology innovator, today announces the publication of the SP301 study in the Pain and Therapy Journal that demonstrates the safety and efficacy of Relivion MG, Neurolief’s CE-marked and FDA cleared wearable neuromodulation system for at-home treatment of migraine with remote physician monitoring. ...
Key data highlights with the Evoke® System to include holistic composite treatment outcomes for disrupting the chronic pain cycle; opioid-sparing effects of therapy; real-world results; and cost-effectiveness compared to open-loop stimulation. Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of ...
The company is already in the clinical stage with a commercially-viable neuroprosthesis for the treatment of paralysis and is developing the first endovascular implantable neuromodulation therapy. Future applications may include the potential to diagnose and treat conditions of the nervous system, including Parkinson’s disease, epilepsy, depression, and ...
The clinical-stage company is developing a neuroprosthesis for the treatment of paralysis and the first endovascular implantable neuromodulation therapy. Future applications may include the potential to diagnose and treat conditions of the nervous system, including Parkinson’s disease, epilepsy, depression, and hypertension. ...
He was the national principal Investigator for the Medtronic InSite trial which demonstrated superior success of sacral neuromodulation when compared to standard medical therapy and the durability of sacral neuromodulation out through 5- years of follow-up. ...
The company is in the clinical stage with a commercial neuroprosthesis for the treatment of paralysis and is developing the first endovascular implantable neuromodulation therapy. Future applications may include the potential to diagnose and treat conditions of the nervous system, including Parkinson’s disease, epilepsy, depression, and hypertension, as ...
Transformative closed-loop technology senses the spinal cord’s response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment Long-term results published in two premier clinical journals show clinically meaningful improvements in pain relief, physical and emotional functioning, sleep quality, and health-related quality of life Saluda ...
Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies designed to treat debilitating neurological disorders, today announced the appointment of Robert (Bob) Palmisano to its Board ...
Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, earlier this quarter finalized US $125 million in equity financing, led by existing ...
Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced the appointment of Doug Godshall as Chairman of its Board of ...
The technology will transform three medical verticals: prosthetics, therapy, and diagnostics. “I believe that using the blood vessels will be the solution for the wide adoption of BCI,” said Jordi Parramon, PhD. ...
Saluda Medical Pty Limited (“Saluda Medical”), a global company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced long-term results of its double-blind Level 1 EVOKE randomized controlled ...
The company is already in the clinical stage with a commercially-viable neuroprosthesis for the treatment of paralysis and is developing the first endovascular implantable neuromodulation therapy. Future applications may include the potential to diagnose and treat conditions of the nervous system, including Parkinson’s disease, epilepsy, depression, and ...
Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine, today announced multiple presentations of long-term clinical results and ISH subgroup data from the MODERATO II study of BackBeat Cardiac ...
SOUTH SAN FRANCISCO, Calif., August 25, 2021 – Presidio Medical, Inc., a clinical-stage medical technology company developing a transformational neuromodulation platform, today announced research involving the company’s novel ULF™ neuromodulation therapy has been published in Science Translational Medicine. The publication, ...
The data demonstrated that BackBeat Cardiac Neuromodulation Therapy™ (CNT™), a programmable and adjustable bioelectronic therapy delivered via an active implantable cardiac pulse generator, significantly reduced 24-hour ambulatory systolic blood pressure (aSBP) in patients with persistent hypertension and a clinical indication for a ...
Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company focused on developing transformative therapeutic products for large unmet medical needs in procedure-based medicine, today announced that long-term follow-up data on hypertensive patients from the control group of the MODERATO II study who received crossover treatment with ...